Company Information


State: MA 
Zip Code: 02109 
Telephone: 857-415-4774 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a biopharmaceutical company focused on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal, or GI, disorders where improper flow or absorption of bile causes serious medical conditions for which there is high unmet need. The initial target indication for our lead product candidate, A4250, is progressive familial intrahepatic cholestasis, or PFIC, a rare, life-threatening genetic disorder affecting young children for which there is currently no approved drug treatment. A4250 is currently being evaluated in a Phase 2 clinical trial in children with chronic cholestasis that is intended to support a planned Phase 3 clinical trial in patients with PFIC. In addition to PFIC and subject to obtaining additional capital, we plan to consider conducting future clinical development of A4250 as a treatment for other pediatric cholestatic liver diseases and disorders.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2016 Leverage 2016
Net Inc/Comm Equity-0.27Total Liab/Total Assets0.26
Net Inc/Total Assets-0.33Total Liab/Inv Cap0.38
Net Inc/Inv Cap-0.48Total Liab/Comm Equity0.21
Pretax Inc/Net Sales-1.43Interest Coverage Ratio-11.35
Net Inc/Net Sales-1.44Curr Debt/Equity0.08
Cash Flow/Net Sales-0.77LTD/EquityNA
SG&A/NetSales1.37Total Debt/Equity0.08
Asset Utilization   Liquidity  
Net Receivables Turnover61.43Quick Ratio2.43
Inventory TurnoverNACurrent Ratio2.43
Inventory Day SalesNANet Rec/Curr Assets0.01
Net Sales/Work Cap0.63Inv/Curr AssetsNA
Net Sales/PP&E541.14  

Income Statement (Millions)

  9/30/2017 6/30/2017 3/31/2017
Total Revenues(Net Sales) 0.00 0.00 0.00
Cost of Goods Sold NA NA NA
Selling & Admin Exps 3.31 3.65 3.29
Operating Income -6.53 -6.61 -6.10
Interest Exp -0.40 0.15 0.25
Pretax Income -6.51 -6.18 -6.67
Other Income 0.00 0.59 -0.33
Net Income Bef Extraordinary ... NA NA NA
Net Income -6.51 -6.18 -6.67

Balance Sheet (Millions)

Assets 9/30/2017 6/30/2017 3/31/2017
Cash & Short Term Investments 57.07 62.60 20.14
Receivables - Total 0.74 0.66 0.64
Inventories - Total NA NA NA
Total Current Assets 58.14 63.73 21.34
Net Property, Plant & Equipment 0.19 0.16 0.11
Total Assets 77.09 82.68 40.30
Accounts Payable 6.15 5.15 5.26
Debt in Current Liabilities 1.47 1.93 2.49
Total Current Liabilities 7.93 7.38 9.07
Long-Term Debt NA NA NA
Total Liabilities 7.97 7.42 9.10
Stockholder's Equity      
Minority Interest NA NA NA
Preferred Stock NA NA NA
Common Stock 0.09 0.09 0.06
Retained Earnings -45.30 -38.79 -32.62
Treasury Stock NA NA NA
Total Stockholders' Equity 69.12 75.25 31.21
Total Liabilities and Stockholders' Equity 77.09 82.68 40.30

Cash Flow Summary (Millions)

Categories 9/30/2017 6/30/2017 3/31/2017
Net Cash Provided by Operating Activities -5.19 -5.90 -8.53
Net Cash Provided by Investing Activities -0.04 -0.05 -0.10
Net Cash Provided by Financing Activities -0.36 47.71 -0.79

Annual Summary Data (Millions)

Year Sales Net Income EPS
Growth RatesInfinity----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own

Report Date : 3/12/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.